Cargando…

A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib

Envenomation by elapid snakes primarily results in neurotoxic symptoms and, consequently, are the primary focus of therapeutic research concerning such venoms. However, mounting evidence suggests these venoms can additionally cause coagulopathic symptoms, as demonstrated by some Asian elapids and Af...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrahman, Arif, Kazandjian, Taline D., Still, Kristina B. M., Slagboom, Julien, Somsen, Govert W., Vonk, Freek J., Casewell, Nicholas R., Kool, Jeroen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695013/
https://www.ncbi.nlm.nih.gov/pubmed/36355986
http://dx.doi.org/10.3390/toxins14110736
_version_ 1784837950382538752
author Arrahman, Arif
Kazandjian, Taline D.
Still, Kristina B. M.
Slagboom, Julien
Somsen, Govert W.
Vonk, Freek J.
Casewell, Nicholas R.
Kool, Jeroen
author_facet Arrahman, Arif
Kazandjian, Taline D.
Still, Kristina B. M.
Slagboom, Julien
Somsen, Govert W.
Vonk, Freek J.
Casewell, Nicholas R.
Kool, Jeroen
author_sort Arrahman, Arif
collection PubMed
description Envenomation by elapid snakes primarily results in neurotoxic symptoms and, consequently, are the primary focus of therapeutic research concerning such venoms. However, mounting evidence suggests these venoms can additionally cause coagulopathic symptoms, as demonstrated by some Asian elapids and African spitting cobras. This study sought to investigate the coagulopathic potential of venoms from medically important elapids of the genera Naja (true cobras), Hemachatus (rinkhals), and Dendroaspis (mambas). Crude venoms were bioassayed for coagulant effects using a plasma coagulation assay before RPLC/MS was used to separate and identify venom toxins in parallel with a nanofractionation module. Subsequently, coagulation bioassays were performed on the nanofractionated toxins, along with in-solution tryptic digestion and proteomics analysis. These experiments were then repeated on both crude venoms and on the nanofractionated venom toxins with the addition of either the phospholipase A(2) (PLA(2)) inhibitor varespladib or the snake venom metalloproteinase (SVMP) inhibitor marimastat. Our results demonstrate that various African elapid venoms have an anticoagulant effect, and that this activity is significantly reduced for cobra venoms by the addition of varespladib, though this inhibitor had no effect against anticoagulation caused by mamba venoms. Marimastat showed limited capacity to reduce anticoagulation in elapids, affecting only N. haje and H. haemachatus venom at higher doses. Proteomic analysis of nanofractionated toxins revealed that the anticoagulant toxins in cobra venoms were both acidic and basic PLA(2)s, while the causative toxins in mamba venoms remain uncertain. This implies that while PLA(2) inhibitors such as varespladib and metalloproteinase inhibitors such as marimastat are viable candidates for novel snakebite treatments, they are not likely to be effective against mamba envenomings.
format Online
Article
Text
id pubmed-9695013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96950132022-11-26 A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib Arrahman, Arif Kazandjian, Taline D. Still, Kristina B. M. Slagboom, Julien Somsen, Govert W. Vonk, Freek J. Casewell, Nicholas R. Kool, Jeroen Toxins (Basel) Article Envenomation by elapid snakes primarily results in neurotoxic symptoms and, consequently, are the primary focus of therapeutic research concerning such venoms. However, mounting evidence suggests these venoms can additionally cause coagulopathic symptoms, as demonstrated by some Asian elapids and African spitting cobras. This study sought to investigate the coagulopathic potential of venoms from medically important elapids of the genera Naja (true cobras), Hemachatus (rinkhals), and Dendroaspis (mambas). Crude venoms were bioassayed for coagulant effects using a plasma coagulation assay before RPLC/MS was used to separate and identify venom toxins in parallel with a nanofractionation module. Subsequently, coagulation bioassays were performed on the nanofractionated toxins, along with in-solution tryptic digestion and proteomics analysis. These experiments were then repeated on both crude venoms and on the nanofractionated venom toxins with the addition of either the phospholipase A(2) (PLA(2)) inhibitor varespladib or the snake venom metalloproteinase (SVMP) inhibitor marimastat. Our results demonstrate that various African elapid venoms have an anticoagulant effect, and that this activity is significantly reduced for cobra venoms by the addition of varespladib, though this inhibitor had no effect against anticoagulation caused by mamba venoms. Marimastat showed limited capacity to reduce anticoagulation in elapids, affecting only N. haje and H. haemachatus venom at higher doses. Proteomic analysis of nanofractionated toxins revealed that the anticoagulant toxins in cobra venoms were both acidic and basic PLA(2)s, while the causative toxins in mamba venoms remain uncertain. This implies that while PLA(2) inhibitors such as varespladib and metalloproteinase inhibitors such as marimastat are viable candidates for novel snakebite treatments, they are not likely to be effective against mamba envenomings. MDPI 2022-10-27 /pmc/articles/PMC9695013/ /pubmed/36355986 http://dx.doi.org/10.3390/toxins14110736 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arrahman, Arif
Kazandjian, Taline D.
Still, Kristina B. M.
Slagboom, Julien
Somsen, Govert W.
Vonk, Freek J.
Casewell, Nicholas R.
Kool, Jeroen
A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib
title A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib
title_full A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib
title_fullStr A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib
title_full_unstemmed A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib
title_short A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib
title_sort combined bioassay and nanofractionation approach to investigate the anticoagulant toxins of mamba and cobra venoms and their inhibition by varespladib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695013/
https://www.ncbi.nlm.nih.gov/pubmed/36355986
http://dx.doi.org/10.3390/toxins14110736
work_keys_str_mv AT arrahmanarif acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT kazandjiantalined acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT stillkristinabm acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT slagboomjulien acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT somsengovertw acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT vonkfreekj acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT casewellnicholasr acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT kooljeroen acombinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT arrahmanarif combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT kazandjiantalined combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT stillkristinabm combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT slagboomjulien combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT somsengovertw combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT vonkfreekj combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT casewellnicholasr combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib
AT kooljeroen combinedbioassayandnanofractionationapproachtoinvestigatetheanticoagulanttoxinsofmambaandcobravenomsandtheirinhibitionbyvarespladib